Filing Analysis
Gain Therapeutics, Inc. filed an 8-K to announce its second quarter financial results for the period ended June 30, 2026, and provided a general business update via press release.
π Key Facts
- Report date: August 11, 2026
- Reporting period: Second Quarter ended June 30, 2026
- The filing includes an announcement of financial results and a business update (Exhibit 99.1).
- Company is classified as an emerging growth company.
Gain Therapeutics announced that its current cash and cash equivalents are expected to fund operations only through the second quarter of 2027. This liquidity runway is contingent upon completing clinical milestones in late 2026.
π© Red Flags
- Limited cash runway (approximately 9 months from the filing date of July 16, 2026).
- Heavy reliance on successful clinical trial outcomes to justify future funding/operations.
- Implicit need for capital raise within the next 6-9 months to sustain operations beyond Q2 2027.
π Key Facts
- Current cash and cash equivalents are anticipated to fund operations into Q2 2027.
- Company expects to complete Phase 1b open-label extension in October 2026.
- Company plans to initiate a Phase 2 clinical study during Q3 2026.
Gain Therapeutics announced that the FDA has authorized its Investigational New Drug (IND) application for GT-02287. This authorization enables the company to begin Phase 2 clinical development of the drug for Parkinsonβs disease, with trials expected to start in Q3 2026.
π Key Facts
- FDA authorized IND application for GT-02287 on June 29, 2026.
- GT-02287 is being developed for Parkinson's disease (with or without GBA1 mutation).
- Phase 2a study will include participants in the U.S., Australia, and Europe.
- Clinical development initiation is anticipated for Q3 2026.
Gain Therapeutics, Inc. held its annual meeting of stockholders on June 24, 2026. The company successfully elected seven directors and ratified the appointment of Ernst & Young AG as its independent auditor for the fiscal year ending December 31, 2026.
π Key Facts
- Annual Meeting held on June 24, 2026.
- Seven directors were elected: Gene Mack, Dov Goldstein, M.D., Hans Peter Hasler, Khalid Islam, Ph.D., Gwen Melincoff, Claude Nicaise, M.D., and Jeffrey Riley.
- Ratification of Ernst & Young AG as the independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved with 25,865,468 votes 'For'.
- The company is classified as an emerging growth company.
Gain Therapeutics, Inc. disclosed interim clinical and biomarker data from a Phase 1b study extension for GT-02287 in Parkinson's disease patients. The data shows a significant reduction in CSF GluSph levels and positive trends in MDS-UPDRS scores, particularly for patients with high baseline GluSph.
π Key Facts
- Interim data from Part 2 (nine-month extension) of Phase 1b study of GT-02287 released May 26, 2026.
- 16 of 19 participants from Part 1 continued into the extension study.
- CSF GluSph levels decreased by an average of 81% after 90 days of treatment in participants with elevated baseline levels.
- Patients with high baseline GluSph showed a 4.8 point difference in MDS-UPDRS Part II and III scores compared to low baseline GluSph patients at Day 150.
- Participants reported unsolicited benefits including improved smell, taste, balance, gait, and sleep.
- A Data Monitoring Committee meeting on March 5, 2026, concluded the study should continue without changes.
Gain Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2026, and provided a general business update via a press release.
π Key Facts
- Announced Q1 2026 financial results on May 11, 2026
- Furnished press release as Exhibit 99.1
- Reported under Item 2.02 (Results of Operations and Financial Condition)
- Signed by CEO Gene Mack
Gain Therapeutics, Inc. announced its financial results for the fiscal year ended December 31, 2025, and provided a business update. The information was furnished via a press release as part of a routine Item 2.02 filing.
π Key Facts
- The filing reports financial results for the full year ended December 31, 2025.
- The announcement was made on March 26, 2026.
- The report includes a business update in addition to financial metrics.
- The filing was signed by Gene Mack, Chief Executive Officer.
Gain Therapeutics announced positive clinical and biomarker data from its Phase 1b study of GT-02287 in Parkinson's Disease at the AD/PD 2026 conference. The data demonstrated substantial biomarker reductions and stable clinical scores over 150 days, alongside the introduction of a new IND-ready preclinical candidate.
π Key Facts
- 16 out of 19 participants who completed Part 1 of the Phase 1b study elected to continue into the 9-month extension (Part 2).
- A Data Monitoring Committee (DMC) meeting on March 5, 2026, recommended the study continue without changes.
- Participants with elevated baseline GluSph levels saw substantial decreases in the biomarker after 90 days of treatment.
- MDS-UPDRS scores remained stable over 150 days of dosing as of March 10, 2026.
- A 6.7-point difference in MDS-UPDRS Part II and III scores was observed between high and low baseline GluSph groups at Day 150.
- The company announced GT-04686 as a new lead chemical series ready for IND-enabling studies.
Gain Therapeutics, Inc. filed an 8-K to disclose an investor presentation via Item 7.01 (Regulation FD). The filing serves as a mechanism to communicate business updates to the public through supplemental slides.
π Key Facts
- Filed on February 3, 2026.
- The company is an 'emerging growth company'.
- The filing includes an Investor Presentation (Exhibit 99.1) describing the company's business.
- Information is furnished under Item 7.01 and is not considered 'filed' for purposes of Section 18 liability.
Gain Therapeutics announced positive exploratory endpoint results from its Phase 1b study of GT-02287 in Parkinsonβs Disease patients, showing significant decreases in GluSph levels. The company also confirmed it has sufficient capital to fund operations through year-end 2026.
π© Red Flags
- Clinical stage company (high risk inherent to biotech/clinical trial outcomes).
π Key Facts
- GT-02287 showed a large decrease in glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF) after 90 days of treatment in patients with Parkinson's Disease.
- Phase 1b Part 1 (90-day dosing) has concluded; 15 of 19 participants (79%) enrolled in the nine-month extension (Part 2).
- The Phase 1b extension is anticipated to conclude in September 2026.
- Data monitoring committee recommended continuing the study with no changes.
- Company maintains a capital position sufficient to fund operations through the end of the Phase 1b extension and year-end 2026.
Gain Therapeutics, Inc. has filed a prospectus supplement to expand its 'at the market' (ATM) offering program, allowing for the sale of up to $35,530,980.56 in common stock through Oppenheimer & Co. Inc.
π© Red Flags
- Significant potential dilution: The company is seeking to raise over $35.5 million through common stock issuance, which will dilute existing shareholders.
π Key Facts
- The company is increasing/utilizing an ATM offering via a Distribution Agreement with Oppenheimer & Co. Inc.
- Total amount of new potential equity issuance: $35,530,980.56
- Prior aggregate sales under the existing agreement total: $14,469,019.44
- The offering is conducted via a shelf registration statement on Form S-3 (File No. 333-287622) which became effective on November 26, 2025.
- Lowenstein Sandler LLP provided the legal opinion for the validity of the shares.
Gain Therapeutics, Inc. filed an 8-K to announce its third quarter financial results for the period ended September 30, 2025, and provided a general business update.
π Key Facts
- Report date: November 12, 2025
- Reporting period: Third Quarter ended September 30, 2025
- The filing includes an earnings press release as Exhibit 99.1
- Company is classified as an 'emerging growth company'
Gain Therapeutics, Inc. hosted a virtual Key Opinion Leader (KOL) event focused on biomarkers and clinical endpoints related to their GT-02287 program. The company provided a presentation contextualizing emerging data for the drug candidate.
π Key Facts
- Event Date: October 14, 2025
- Topic: 'Biomarkers, Clinical Endpoints, and the Path to Disease Modification: Contextualizing the emerging data from GT-02287'
- Featured Speakers: Karl Kieburtz, M.D., M.P.H. (University of Rochester) and Kenneth Marek, M.D. (Institute for Neurodegenerative Disorders)
- The information was furnished under Item 7.01 (Regulation FD) and is not considered 'filed' for liability purposes.
Gain Therapeutics, Inc. announced the immediate resignation of Eric Richman from its Board of Directors effective October 6, 2025. The company noted that the resignation was not due to any disagreement regarding operations, policies, or practices.
π Key Facts
- Eric Richman resigned from the Board of Directors on October 6, 2025.
- The resignation is effective immediately.
- The departure was not due to disagreements with the Company's operations, policies, or practices.
- As a result of the resignation, the Board size has been reduced from eight members to seven.
Gain Therapeutics presented preliminary Phase 1b clinical data for GT-02287 in Parkinsonβs disease patients at the International Congress of Parkinsonβs Disease and Movement Disorders. The data suggests potential disease-slowing effects and a favorable safety profile, leading to regulatory approval for a study extension.
π© Red Flags
- Transient increase in liver enzymes (alkaline phosphatase) observed in some participants, though they normalized during dosing.
π Key Facts
- Preliminary Phase 1b data for GT-02287 in Parkinson's disease (PD) patients presented on October 6, 2025.
- GT-022287 was reported as safe and well-tolerated over 90 days with no treatment-emergent serious adverse events.
- Observed transient increases in alkaline phosphatase and liver enzymes that normalized despite ongoing dosing.
- Participants showed improvement in MDS-UPDRS Part II and III scores by Day 90, suggesting a potential disease-slowing effect.
- Plasma pharmacokinetics (PK) were consistent across 14 sampled participants and within the projected therapeutic range.
- Australian health authorities approved a study extension allowing treatment for up to 12 months.
Gain Therapeutics, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2025, and provided a general business update via press release.
π Key Facts
- Report date: August 12, 2025
- Reporting period: Second Quarter ended June 30, 2025
- The filing includes an announcement of financial results and a business update (Exhibit 99.1).
- Company is classified as an 'emerging growth company'.
Gain Therapeutics, Inc. entered into an underwriting agreement with Newbridge Securities Corporation to launch a public offering of common stock and warrants for approximately $7.0 million in gross proceeds.
π© Red Flags
- Significant dilution potential due to the issuance of over 2.25 million warrants (representing a 1:2 warrant-to-share ratio).
- The effective share price ($1.55) is significantly lower than the current market pricing implied by the offering structure, suggesting heavy discounting or capital need.
- Underwriter's Warrants are being issued via unregistered sale (Item 3.02).
π Key Facts
- Offering size: 4,501,640 shares of Common Stock and 2,250,820 Warrants.
- Gross proceeds: Approximately $7.0 million; Net proceeds expected to be approximately $6.3 million.
- Pricing: The public offering price is $3.11 per set (two shares + one warrant), yielding an effective price of $1.55 per share and $0.01 per Warrant.
- Warrant terms: Exercise price of $1.65 per share; exercisable for five years; cashless exercise permitted if registration is unavailable.
- Underwriter's Warrants: The Underwriter receives warrants to purchase up to 315,115 shares (or up to 362,382 if over-allotment is exercised) at an exercise price of $1.94 per share.
- Lock-up: Company agreed to restrictions on the issuance and sale of Common Stock for a 90-day period following the Underwriting Agreement date.
Gain Therapeutics announced an update regarding its Phase 1b clinical study for GT-02287 in Parkinsonβs Disease. The company reported faster-than-anticipated enrollment and a revised timeline that will allow for earlier delivery of biomarker data in Q4 2025.
π© Red Flags
- Mention of a two-month delay in protocol implementation (though enrollment has since accelerated).
π Key Facts
- Phase 1b study reached 16 participants as of June 30, 2025 (target was 15-20).
- Independent data monitoring committee recommended continuing the study with no dose changes; no serious treatment-emergent adverse events reported.
- Biomarker analysis for CSF samples is now expected in Q4 2025 instead of Q1 2026 due to accelerated enrollment.
- The company plans to seek extension of the dosing period in Australia and will provide an update on this by the end of Q3 2025.
- Long-term chronic toxicology studies are nearing completion.
Gain Therapeutics, Inc. held its annual meeting of stockholders on June 24, 2025, where shareholders approved a significant increase in authorized common stock from 50 million to 100 million shares. The company also ratified Ernst & Young AG as its independent auditor and elected eight directors.
π© Red Flags
- Significant increase in authorized shares (doubling from 50M to 100M) often precedes a secondary equity offering or potential dilution for existing shareholders.
π Key Facts
- Authorized shares increased from 50,000,000 to 100,000,000 via Certificate of Amendment filed in Delaware on June 24, 2025.
- Proposal to increase authorized shares was approved with 16,302,195 votes 'For' and 2,239,298 votes 'Against'.
- Ratification of Ernst & Young AG as independent registered public accounting firm for fiscal year ending Dec 31, 2025 was approved.
- Eight directors were elected to hold office for a term of one year: Gene Mack, Dov Goldstein, M.D., Hans Peter Hasler, Khalid Islam, Ph.D., Gwen Melincoff, Claude Nicaise, M.D., Eric I. Richman, and Jeffrey Riley.
- The company is classified as an emerging growth company.
Gain Therapeutics, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2025, and provided a business update via press release.
π Key Facts
- Report date: May 14, 2025
- Reporting period: First quarter ended March 31, 2025
- The filing includes an announcement of financial results and a business update (Exhibit 99.1)
- Company is classified as an emerging growth company
Gain Therapeutics, Inc. announced preclinical data for its lead candidate GT-02287 and provided the design for its upcoming Phase 1b clinical study targeting Parkinson's disease. The company also updated its investor presentation to reflect these developments.
π Key Facts
- GT-02287 showed potential in preclinical models to rescue motor deficits and prevent complex behavior deficits in both GBA1 and idiopathic Parkinsonβs disease.
- Preclinical data indicated reduction in several biomarkers: aggregated Ξ±-synuclein, IRE-1, LAMP-1, Miro1, phospho-Tau, and Iba-1.
- Phase 1b study will assess safety, tolerability, and pharmacokinetics (PK) over three months of dosing.
- Early biomarker analysis from Phase 1b is expected mid-year 2025 to inform Phase 2 planning.
- Complete analysis of Phase 1b endpoints is anticipated in Q4 2025.
Gain Therapeutics, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024, and provided a general business update via press release.
π Key Facts
- Report date: March 27, 2025
- The filing covers financial results for the year ended December 31, 2024
- Includes a business update alongside financial results
- Company is an emerging growth company
Gain Therapeutics, Inc. filed an 8-K to furnish a press release containing an operational update under Regulation FD disclosure.
π Key Facts
- The filing was made on February 6, 2025.
- The company issued a press release providing an operational update (Exhibit 99.1).
- The information is furnished under Item 7.01 and is not considered 'filed' for purposes of Section 18 liability.
Gain Therapeutics received a deficiency notice from Nasdaq for failing to meet the Market Value of Listed Securities (MVLS) requirement between November 14 and December 27, 2024. However, the company has since regained compliance as of January 15, 2025.
π© Red Flags
- Historical failure to meet Nasdaq minimum market value requirements (MVLS).
- Recent volatility or decline in market capitalization that triggered a deficiency notice.
π Key Facts
- Received MVLS Deficiency Notice from Nasdaq Staff on January 8, 2025.
- Non-compliance period: November 14, 2024, to December 27, 2024.
- The deficiency was related to the Market Value of Listed Securities (MVLS) falling below the $50 million minimum requirement.
- Company regained compliance with the MVLS Requirement as of January 14, 2025.
- Nasdaq Staff provided written confirmation of compliance on January 15, 2025.
Gain Therapeutics, Inc. announced a leadership reshuffle effective January 6, 2025, involving the appointment of Gene Mack as President and CEO and Gianluca Fuggetta as Principal Financial Officer.
π© Red Flags
- Internal promotion/reshuffle: The CEO was previously the CFO, which can sometimes indicate rapid turnover or internal restructuring in micro-cap firms.
- Executive compensation complexity: Inclusion of significant equity options and severance triggers (change in control) is standard but increases potential dilution and liability.
π Key Facts
- Gene Mack appointed President and CEO, effective Jan 6, 2025; he was previously CFO and interim CEO.
- Gene Mack's new compensation includes a $500,000 base salary and a target annual cash bonus of 50%.
- Mack received an option to purchase up to 271,325 shares at an exercise price of $2.44.
- Gianluca Fuggetta appointed Principal Financial Officer; previously VP of Finance and Principal Accounting Officer.
- Fuggetta's compensation includes a base salary of CHF 200,000 and a target annual cash bonus of 30%.
Gain Therapeutics, Inc. announced on December 23, 2024, that it has received regulatory approval in Australia to initiate a Phase 1b clinical trial for its lead drug candidate, GT-02287, intended for the treatment of Parkinson's disease.
π© Red Flags
- None identified in this filing.
π Key Facts
- Received approval in Australia to initiate a Phase 1b clinical trial for GT-02287.
- GT-02287 is an allosteric small molecule targeting Parkinson's disease (PD) with or without GBA1 mutation.
- The Phase 1b trial will assess safety and tolerability of a 13.5 mg/kg/day dose for three months.
- Enrollment in the Australian sites is expected to complete in Spring 2025.
- Clinical data from the Phase 1b study is anticipated in mid-2025.
- Phase 1 studies in healthy volunteers previously showed >50% increase in glucocerebrosidase (GCase) activity.
Gain Therapeutics, Inc. filed an 8-K to announce its third quarter financial results for the period ended September 30, 2024, and provided a general business update via press release.
π© Red Flags
- Interim CEO designation suggests potential leadership instability or transition in the executive suite.
π Key Facts
- Reported date: November 14, 2024
- Reporting period: Third Quarter ended September 30, 2024
- The filing includes an earnings press release (Exhibit 99.1) and a business update.
- Gene Mack serves as both CFO and Interim CEO.
Gain Therapeutics, Inc. has regained compliance with Nasdaq's minimum Market Value of Listed Securities (MVLS) requirement. The company is now in full compliance with all Nasdaq Global Market listing requirements, resolving the deficiency previously reported in July 2024.
π© Red Flags
- Historical non-compliance with Nasdaq listing requirements (previously reported July 12, 2024).
π Key Facts
- The Company received notice from Nasdaq Staff that it has regained compliance with the $50 million MVLS Requirement (Nasdaq Listing Rule 5450(b)(2)(A).
- Compliance was achieved prior to the January 7, 2025 deadline.
- The matter regarding the MVLS deficiency is now officially closed.
Gain Therapeutics announced preclinical data for its product candidate GT-02287, demonstrating efficacy in animal models of GBA-1 and idiopathic Parkinsonβs disease. The data suggests improvements in motor/cognitive function and neuroprotection across multiple models.
π Key Facts
- Announced preclinical data for GT-02287 on October 7, 2024.
- Observed rescue of motor and cognitive function in GBA-1 and idiopathic Parkinsonβs disease animal models.
- Efficacy was persistent even after a one-week washout period following discontinuation of treatment.
- In vitro data showed reduction in mitochondrial reactive oxygen species (ROS), amelioration of lysosomal pathology, and reduced Ξ±-synuclein aggregation.
- GT-02287 demonstrated reduction in Tau accumulation in both GBA L444P mutant and wild-type cell lines.
Gain Therapeutics, Inc. entered into an Equity Distribution Agreement with Oppenheimer & Co. Inc. for an at-the-market (ATM) offering program of up to $50.0 million in common stock.
π© Red Flags
- Potential for significant shareholder dilution through the issuance of new common stock to raise capital.
π Key Facts
- Entered into an Equity Distribution Agreement on September 6, 2024.
- Agent: Oppenheimer & Co. Inc.
- Aggregate offering price: Up to $50.0 million of common stock.
- Commission rate: 3.0% of gross sales proceeds.
- The offering will be conducted via an at-the-market (ATM) program under a previously effective S-3 shelf registration statement.
Gain Therapeutics, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2024, and provided a general business update via press release.
π© Red Flags
- Interim CEO role may indicate recent management instability or transition, though common in micro-caps.
π Key Facts
- Report date: August 8, 2024
- Reporting period: Second Quarter ended June 30, 2024
- The filing includes an announcement of financial results and a business update (Exhibit 99.1)
- Gene Mack serves as both CFO and Interim CEO
Gain Therapeutics received a deficiency notice from Nasdaq because its Market Value of Listed Securities (MVLS) fell below the $50 million minimum requirement for the period of May 8, 2024, to July 10, 2024. The company has until January 7, 2025, to regain compliance.
π© Red Flags
- Delisting notice/non-compliance with Nasdaq listing rules
- Market capitalization/MVLS has fallen below required thresholds, indicating significant loss in shareholder value or market interest
π Key Facts
- Received MVLS Deficiency Notice from Nasdaq on June 11, 2024.
- MVLS was below the $50 million minimum requirement between May 8, 2024, and July 10, 2024.
- Compliance deadline (Compliance Date) is January 7, 2025.
- To regain compliance, MVLS must close at $50 million or more for at least ten consecutive business days during the compliance period.
- Failure to comply may result in delisting from the Nasdaq Global Market.
Gain Therapeutics announced the successful completion of dosing in the multiple ascending dose (MAD) portion of its Phase 1 study for GT-02287, a small molecule therapy targeting Parkinsonβs Disease. The company reported no discontinuations or serious adverse events during this phase.
π Key Facts
- Completed dosing in the Multiple Ascending Dose (MAD) part of the Phase 1 study for GT-02287.
- GT-02287 is a novel small molecule therapy for Parkinsonβs Disease.
- No serious adverse events (SAEs) were reported during the MAD dosing phase.
- No participant discontinuations were reported during the MAD dosing phase.
Gain Therapeutics, Inc. announced the departure of CEO Matthias Alder effective June 25, 2024, via mutual agreement. The company has appointed CFO Gene Mack as Interim CEO and Dr. Khalid Islam as Executive Chairman to provide advisory support during the transition.
π© Red Flags
- Sudden departure of the Chief Executive Officer (CEO) creates leadership instability.
- Transition to an 'Interim' CEO often suggests a period of uncertainty or lack of immediate permanent succession planning.
- Significant cash outflow for severance: 12 months of salary plus COBRA premiums.
π Key Facts
- CEO Matthias Alder resigned from his position and the Board of Directors effective June 25, 2024.
- Alder will receive a lump sum payment equal to 12 months of base salary and 12 months of COBRA premiums.
- Unvested stock options and RSUs for Alder will vest through the one-year anniversary of his departure (June 25, 2025).
- CFO Gene Mack appointed as Interim CEO effective June 25, 2024; no additional compensation for this role.
- Dr. Khalid Islam appointed Executive Chairman of the Board effective June 25, 2024.
Gain Therapeutics, Inc. held its annual meeting of stockholders on June 24, 2024. The company successfully elected eight directors and ratified the appointment of Ernst & Young AG as its independent registered public accounting firm.
π Key Facts
- Annual Meeting held on June 24, 2024.
- Eight directors were elected: Matthias Alder, Dov Goldstein, M.D., Hans Peter Hasler, Khalid Islam, Ph.D, Gwen Melincoff, Claude Nicaise, M.D., Eric I. Richman, and Jeffrey Riley.
- Ratification of Ernst & Young AG as the independent registered public accounting firm for the fiscal year ending December 31, 2024 was approved with 11,836,784 votes in favor.
Gain Therapeutics, Inc. entered into an underwriting agreement on June 13, 2024, to conduct a public offering of common stock and pre-funded warrants. The offering aims to raise approximately $10.1 million in net proceeds.
π© Red Flags
- Significant dilution potential due to the issuance of over 7 million shares and substantial warrant coverage.
- Pre-funded warrants allow for immediate economic exposure with minimal cash outlay, often used in distressed or high-growth capital needs.
- Restrictions on 'Variable Rate Transactions' suggest the company is limiting its ability to raise further capital through certain dilutive methods in the near term.
π Key Facts
- Offering size: 7,116,547 shares of common stock and up to 1,031,602 pre-funded warrants.
- Pricing: $1.35 per share of common stock and $1.3499 per pre-funded warrant.
- Expected net proceeds: Approximately $10.1 million after expenses.
- Underwriter: Titan Partners Group LLC (division of American Capital Partners, LLC).
- Warrant terms: Pre-funded warrants are exercisable for one share at $0.0001 per share; Underwriter Warrants are exercisable at $1.6875 per share.
- Restrictions: 60-day restriction on issuing new securities and a 6-month prohibition on 'Variable Rate Transactions' without underwriter consent.
Gain Therapeutics, Inc. filed an 8-K to announce its financial results and a business update for the first quarter ended March 31, 2024.
π Key Facts
- Report date: May 14, 2024
- Reporting period: First quarter ended March 31, 2024
- The filing includes a press release (Exhibit 99.1) regarding financial results and business updates.
- Company is an emerging growth company.
Gain Therapeutics, Inc. announced the appointment of Gene Mack as Chief Financial Officer, Principal Financial Officer, and Secretary, effective April 8, 2024. This follows a period where Gianluca Fuggetta had been serving in an interim capacity as Principal Financial Officer.
π© Red Flags
- Frequent turnover/changes in the PFO role (Gianluca Fuggetta had been serving as interim since March 1, 2024).
π Key Facts
- Gene Mack appointed as CFO, PFO, and Secretary effective April 8, 2024.
- Mr. Mack's annual base salary is set at $370,000 with a target cash bonus of 35%.
- Inducement equity award: up to 200,000 shares of common stock at an exercise price of $3.56 per share, vesting over four years.
- Gianluca Fuggetta will remain as VP of Finance and Principal Accounting Officer.
- Mr. Mack brings significant biotech finance experience, including roles at Imcyse SA and OncoC4, Inc.
Gain Therapeutics, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023, and provided a business update via press release.
π Key Facts
- Report date: March 26, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes an announcement of financial results and a general business update via Exhibit 99.1.
Gain Therapeutics, Inc. announced the resignation of its Chief Financial Officer, C. Evan Ballantyne, effective March 1, 2024. The company has appointed Gianluca Fuggetta as Vice President of Finance and Principal Financial Officer to fill the vacancy while a search for a permanent CFO is conducted.
π© Red Flags
- Sudden departure of the CFO in a micro-cap biotech environment can sometimes signal internal friction or financial reporting concerns, though no restatement was mentioned here.
π Key Facts
- C. Evan Ballantyne resigned as CFO and from all other positions effective March 1, 2024.
- Gianluca Fuggetta appointed as Vice President of Finance and Principal Financial Officer, effective March 1, 2024.
- Fuggetta previously served as Senior Director and Principal Accounting Officer since January 2023.
- The company has initiated a search for a new Chief Financial Officer.
Gain Therapeutics, Inc. filed an 8-K to furnish a press release containing a letter from CEO Matthias Alder to stockholders dated January 31, 2024.
π Key Facts
- The filing is pursuant to Item 7.01 (Regulation FD).
- Includes a stockholder letter from CEO Matthias Alder via Exhibit 99.1.
- The company is an emerging growth company.